Stock Taper
BeyondSpring Inc. is a clinical-stage biopharma focused on cancer therapies, with lead drug Plinabulin in Phase III for chemo-induced neutropenia and NSCLC, plus ongoing immuno-oncology combination research.

Plinabulin, BeyondSpring's lead immunomodulating microtubule-binding agent, is in late-stage trials for NSCLC and chemotherapy-induced neutropenia, showing promising combination therapy results.
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
ALXO | $2.00 | COMPARE |
UNCY | $5.26 | COMPARE |
BMEA | $1.73 | COMPARE |
GUTS | $0.66 | COMPARE |
DTIL | $7.78 | COMPARE |
CAMP | $4.15 | COMPARE |
HYFT | $1.39 | COMPARE |
ATYR | $0.54 | COMPARE |